RE:RE:RE:RE:enough suits!Gbathat wrote: ...I suspect they were brought on for very specific reasons...clinical trial coordination...brain imaging...
But those needs come after selecting the protein(s), the conformation specific epitopes, and producing the antibodies.
So if you are right then Gene should be able to provide us with development timeline much faster than we've experienced.
I suspect these appointments arise now simply because money is finally available and Cashman has wanted to expand in this direction for a while. I think it's a fantastic direction because its drugs produces immediate results, but we need a budget presentation that itemizes it to allay fears that it's not a wholesale change in direction based on post-aducanumab fear of FDA decisions.
As for bashers, nothing said on this board matters to the market. Only two things matter: news and placement share overhang, and I think the overhang will dry up this year.